• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Sacubitril or valsartan versus standard medical therapies in patients with heart failure with preserved ejection fraction: PARALLAX trial

byYuchen DaiandMichael Pratte
November 17, 2021
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized, controlled trial, for patients with heart failure and left ventricular ejection fraction higher than 40%, sacubitril/valsartan treatment compared with standard medical therapy resulted in a significantly greater reduction in plasma N-terminal pro-brain natriuretic peptide levels at 12 weeks.

2. However, there was no significant improvement from baseline 6-minute walk distance at 24 weeks between the treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In patients with heart failure with preserved ejection fraction (HFpEF), the therapeutic effects of sacubitril/valsartan compared to standard medical therapy on surrogate outcome markers such as N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration and submaximal exercise capacity is unclear. This trial, PARALLAX, sought to test the hypothesis that sacubitril/valsartan was more effective than background medication-based individualized comparators in the reduction of NT-proBNP levels and improving submaximal exercise capacity and quality of life in patients with chronic heart failure and a left ventricular ejection fraction (LVEF) higher than 40%. The primary endpoints were change from baseline plasma NT-proBNP level at week 12 and the 6-minute walk distance at week 24. Secondary outcomes included change from baseline quality-of-life measures and New York Heart Association (NYHA) class at 24 weeks. Among 2,572 patients with HFpEF, treatment with sacubitril/valsartan vs standard treatment with enalapril, valsartan, or placebo resulted in a statistically significant reduction in plasma NT-proBNP levels at 12 weeks but no significant change the 6-minute walk distance at 24 weeks. Further research is warranted to assess the specific clinical benefits of sacubitril/valsartan in this patient population. A limitation of this study was that it did not include a run-in therapeutic phase resulting in smaller between-group differences as patients who were intolerant of target drug dosages caused dilution.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Effects of sacubitril/valsartan on N-terminal Pro-B-type natriuretic peptide in heart failure with preserved ejection fraction

RELATED REPORTS

Sodium-glucose cotransporter-2 inhibitors are of intermediate or low economic value in the treatment of heart failure with preserved ejection fraction

Days alive out of hospital after ventricular assist device implantation vary with comorbidity status

NT-proBNP associated with risk for incident heart failure and all-cause mortality

In-Depth [randomized controlled trial]: This randomized, double-blinded, parallel group clinical trial enrolled 2,572 patients (mean age [SD], 72.6 [8.5] years; 1,301 [50.7%] women) with HFpEF from 396 centers in 32 countries between August 2017 and October 2019. At baseline, all patients had a LVEF higher than 40%, elevated NT-proBNP levels, and structural heart disease. Patients were randomized 1:1 to sacubitril/valsartan (n = 1,286; baseline median NT-proBNP levels, 786 pg/mL) vs standard treatment with enalapril, valsartan, or placebo (n = 1,286; baseline median NT-proBNP levels,760 pg/mL). Among 2,240 (87.1%) participants who completed the trial, patients in the sacubitril/valsartan group (adjusted geometric mean ratio to baseline, 0.82 pg/mL) had a significantly greater reduction in NT-proBNP levels than individuals in the comparator group (adjusted geometric mean ratio to baseline, 0.98 pg/mL) with an adjusted geometric mean ratio of 0.84 (95%CI, 0.80 to 0.88; P < .001) after 12 weeks of treatment. At week 24, no significant difference in median change from baseline in the 6-minute walk distance was observed, with an increase of 9.7 m vs 12.2 m (adjusted mean difference, -2.5 m; 95%CI, -8.5 to 3.5; P = .42). Furthermore, there was no significant difference in the mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (12.3 vs 11.8; mean difference, 0.52; 95%CI, -0.93 to 1.97) or improvement in NYHA class (23.6% vs 24.0% of patients; aOR, 0.98; 95%CI, 0.81 to 1.18). The most frequent adverse events in the sacubitril/valsartan group vs the standard treatment group were hypotension (14.1% vs 5.5%), albuminuria (12.3% vs 7.6%), and hyperkalemia (11.6% vs 10.9%).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: heart failurehfpefHFpEF (heart failure with preserved ejection fractionNT-proBNP
Previous Post

#VisualAbstract: Head and neck cancers are highly prevalent among alcohol consumption-associated malignancies in the global population

Next Post

Wellness Check: Exercise

RelatedReports

Cardiology

Sodium-glucose cotransporter-2 inhibitors are of intermediate or low economic value in the treatment of heart failure with preserved ejection fraction

March 16, 2023
Mesenchymal precursor cell transplant did not improve weaning from device support in LVAD patients
Cardiology

Days alive out of hospital after ventricular assist device implantation vary with comorbidity status

February 24, 2023
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

NT-proBNP associated with risk for incident heart failure and all-cause mortality

February 19, 2023
StudyGraphics

#VisualAbstract: Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction

February 15, 2023
Next Post
Adolescents’ muscle strength associated with lower cardiometabolic risk

Wellness Check: Exercise

#VisualAbstract Assessing early tumour response and immune-related adverse events when undergoing combination nivolumab and ipilimumab therapy for advanced melanoma

#VisualAbstract Assessing early tumour response and immune-related adverse events when undergoing combination nivolumab and ipilimumab therapy for advanced melanoma

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Selective serotonin reuptake inhibitor use may be associated with reduced mortality from COVID-19 infection

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Metformin use may decrease risk of osteoarthritis development
  • Intensive blood pressure lowering by non-physician healthcare providers significantly reduces the risk of cardiovascular disease
  • Expectant management of patent ductus arteriosus noninferior to early ibuprofen use
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options